SLA2 and pancreatic ductal adenocarcinoma: Besides, genome-scale analysis to identify prognostic markers in patients with early stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy, found that SLA2 is one of the prognostic markers [4].